Sort by
Keyphrases
Alternative Regimens
16%
Apixaban
16%
Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
16%
Cost-effectiveness
100%
Cost-utility
16%
Dabigatran
16%
Decision Tree
16%
Deep Vein Thrombosis
16%
Dominant Strategy
16%
Enoxaparin
16%
Extended Thromboprophylaxis
16%
Fondaparinux
16%
High Risk
33%
Markov Process
16%
Oncology
16%
One-way Sensitivity Analysis
33%
Post-thrombotic Syndrome
16%
Post-traumatic
100%
Probabilistic Sensitivity Analysis
33%
Pulmonary Bleeding
16%
Pulmonary Embolism
16%
Quality-adjusted Life Years
50%
Risk Index
16%
Rivaroxaban
100%
Robust Preferences
16%
Severely Injured Patients
16%
Subspeciality
16%
Thromboprophylaxis
100%
Trauma Patients
33%
Utility Model
16%
Venous Thromboembolism
50%
Venous Thromboembolism Risk
16%
Willingness-to-pay Threshold
16%
Medicine and Dentistry
Apixaban
16%
Chronic Thromboembolic Pulmonary Hypertension
16%
Cost-Effectiveness Analysis
100%
Dabigatran
16%
Deep Vein Thrombosis
16%
Fondaparinux
16%
Health Care Cost
50%
Oncology
16%
Oral
16%
Post-Thrombotic Syndrome
16%
Preference
33%
Prospective Study
16%
Pulmonary Embolism
16%
Quality Adjusted Life Year
50%
Rivaroxaban
100%
Sequela
16%
Thromboprophylaxis
100%
Venous Thromboembolism
66%